Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- …

The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.

Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

Document Details Form EFFECT Filing Date 19 Apr 2022 Document Date 19 Apr 2022 Form Description EFFECT Filing Group Other Company Cingulate Inc Issuer

idiary of Cingulate with and into CTx (the “Reorganization Merger”). As a result of the Reorg nization Merger, CTx will become a wholly owned subsidiary of Cingulate. Unless otherwise stated or the …

Filing Date 2.1† Agreement and Plan of Merger, dated August 30, 2021, among Cingulate, Inc., Cingulate Therapeutics LLC, and Cingulate Pharma LLC S-1 9/9/2021 Amended and Restated …

Document Details Form DEF 14A Filing Date 22 Jul 2024 Document Date 22 Jul 2024 Form Description Official notification to shareholders of matters to be brought to a vote ("Proxy") Filing Group Proxy …

Document Details Form 4 Filing Date 01 Jul 2025 Document Date 31 Mar 2025 Form Description Statement of changes in beneficial ownership of securities Filing Group 3,4,5 Company Cingulate Inc …